Results 31 to 40 of about 15,828 (290)

Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration

open access: yesTrials, 2009
Background Administration of abciximab during primary percutaneous coronary intervention is an effective adjunctive therapy in the treatment of patients with ST-segment elevation myocardial infarction.
Gu Youlan L   +6 more
doaj   +1 more source

Efficacy and safety of abciximab versus tirofiban in addition to ticagrelor in STEMI patients undergoing primary percutaneous intervention

open access: yesPlatelets, 2022
Platelet glycoprotein IIb/IIIa inhibitors (GPIs) have been part of the adjuvant treatment of acute coronary syndrome for years. However, real-life data regarding the efficacy and safety of GPIs under the current indications are lacking in the setting of ...
Pablo Revilla-Martí   +8 more
doaj   +1 more source

Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients.

open access: yesBritish Journal of Clinical Pharmacology, 2016
OBJECTIVE The present study investigated whether the glycoprotein (GP)IIb/IIIa receptor blocker abciximab might be a successful bridging strategy to achieve adequate levels of platelet inhibition rapidly in cases where prasugrel is used in morphine ...
J. Siller-Matula   +8 more
semanticscholar   +1 more source

Morphine Analgesia Pre-PPCI Is Associated with Prothrombotic State, Reduced Spontaneous Reperfusion and Greater Infarct Size [PDF]

open access: yes, 2017
Schattauer GmbH Stuttgart.The emergency management of ST-elevation myocardial infarction (STEMI) involves treatment with dual-antiplatelet therapy (DAPT) and primary percutaneous coronary intervention (PPCI). Pain is generally treated with opiates, which
Farag, Mohamed   +5 more
core   +1 more source

Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]

open access: yes, 2018
© The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast   +66 more
core   +2 more sources

FLOW DIVERTER DEVICE IN THE ACUTE SETTING OF RUPTURED BLISTER LIKE ANEURYSM: A CASE REPORT [PDF]

open access: yesEuromediterranean Biomedical Journal, 2021
Blister-like aneurysms (BLA) are a rare half-dome-shaped aneurysm, with a broad-based appearance, originating more often from a non-branching site of the supraclinoid internal carotid artery (ICA).
Cesare Gaglaiardo
doaj   +1 more source

Randomized Comparison of Eptifibatide Versus Abciximab in Primary Percutaneous Coronary Intervention in Patients With Acute ST-Segment Elevation Myocardial Infarction Results of the EVA-AMI Trial [PDF]

open access: yes, 2010
ObjectivesThe aim of this study was to compare eptifibatide and abciximab as adjuncts to primary percutaneous coronary intervention (PCI).BackgroundThe glycoprotein (GP) IIb/IIIa receptor inhibitor abciximab as adjunct to primary PCI in patients with ST ...
Banik, Norbert   +11 more
core   +1 more source

Editor's choice : European Society for Vascular Surgery (ESVS) 2020 clinical practice guidelines on the management of acute limb ischaemia

open access: yes, 2020
A
Acosta, Stefan   +33 more
core   +2 more sources

Abciximab reduces mortality in diabetics following percutaneous coronary intervention [PDF]

open access: yes, 2000
OBJECTIVESWe sought to determine whether abciximab therapy at the time of percutaneous coronary intervention (PCI) would favorably affect one-year mortality in patients with diabetes.BACKGROUNDDiabetics are known to have increased late mortality ...
Bhatt, Deepak L   +5 more
core   +1 more source

Are tirofiban and abciximab identical in efficacy? [PDF]

open access: yesEuropean Heart Journal, 2005
We read the paper by Mukherjee et al .1 on similar efficacy outcomes with tirofiban and ReoPro with a lot of interest and considerable reservations. The paper was hand-delivered to me by the representative of one of the drugs in the study with the proud claim that both drugs were equivalent.
openaire   +3 more sources

Home - About - Disclaimer - Privacy